Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

Sharma, S; Kemeny, N; Schwartz, G K; Kelsen, D; O'Reilly, E; Ilson, D; Coyle, J; De Jager, R L; Ducharme, M P; Kleban, S; Hollywood, E; Saltz, L B

Sharma, S; Kemeny, N; Schwartz, G K; Kelsen, D; O'Reilly, E; Ilson, D; Coyle, J; De Jager, R L; Ducharme, M P; Kleban, S; Hollywood, E; Saltz, L B.

Affiliation

Sharma S; Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. sharma1@mskcc.org

Clin Cancer Res ; 7(12): 3963-70, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11751488

Subject(s)

Antineoplastic Agents, Phytogenic/adverse effects; Camptothecin/adverse effects; Enzyme Inhibitors/adverse effects; Neoplasms/drug therapy; Topoisomerase I Inhibitors; Aged; Antineoplastic Agents, Phytogenic/administration & dosage; Antineoplastic Agents, Phytogenic/pharmacokinetics; Camptothecin/administration & dosage; Camptothecin/analogs & derivatives; Camptothecin/pharmacokinetics; Dose-Response Relationship, Drug; Enzyme Inhibitors/administration & dosage; Enzyme Inhibitors/pharmacokinetics; Female; Humans; Infusions, Intravenous; Leukopenia/chemically induced; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms/blood; Neoplasms/urine; Neutropenia/chemically induced; Thrombocytopenia/chemically induced

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Camptothecin / Enzyme Inhibitors / Topoisomerase I Inhibitors / Neoplasms / Antineoplastic Agents, Phytogenic Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2001 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links